Reply to: “Real-world prevalence across 159,872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.” by D. Fabrizio et al.

2021 ◽  
Author(s):  
D.J. McGrail ◽  
P.G. Pilié ◽  
N.U. Rashid ◽  
L. Voorwerk ◽  
M. Slagter ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Real World ◽  
Clinical Utility ◽  
Patients With Cancer

scholarly journals Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4524
Author(s):  
Megan L. Hutchcraft ◽  
Nan Lin ◽  
Shulin Zhang ◽  
Catherine Sears ◽  
Kyle Zacholski ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Real World ◽  
Clinical Utility ◽  
Sequencing Data ◽  
Bioinformatics Pipeline ◽  
Patients With Cancer ◽  
Whole Exome ◽  
Anti Cancer

The purpose of this study was to determine the frequency of clinically actionable treatment-relevant germline pharmacogenomic variants in patients with cancer and assess the real-world clinical utility of universal screening using whole-exome sequencing in this population. Cancer patients underwent research-grade germline whole-exome sequencing as a component of sequencing for somatic variants. Analysis in a clinical bioinformatics pipeline identified clinically actionable pharmacogenomic variants. Clinical Pharmacogenetics Implementation Consortium guidelines defined clinical actionability. We assessed clinical utility by reviewing electronic health records to determine the frequency of patients receiving pharmacogenomically actionable anti-cancer agents and associated outcomes. This observational study evaluated 291 patients with cancer. More than 90% carried any clinically relevant pharmacogenetic variant. At least one disease-relevant variant impacting anti-cancer agents was identified in 26.5% (77/291). Nine patients with toxicity-associated pharmacogenomic variants were treated with a relevant medication: seven UGT1A1 intermediate metabolizers were treated with irinotecan, one intermediate DPYD metabolizer was treated with 5-fluorouracil, and one TPMT poor metabolizer was treated with mercaptopurine. These individuals were more likely to experience treatment-associated toxicities than their wild-type counterparts (p = 0.0567). One UGT1A1 heterozygote died after a single dose of irinotecan due to irinotecan-related adverse effects. Identifying germline pharmacogenomic variants was feasible using whole-exome sequencing. Actionable pharmacogenetic variants are common and relevant to patients undergoing cancer treatment. Universal pharmacogenomic screening can be performed using whole-exome sequencing data originally obtained for quality control purposes and could be considered for patients who are candidates for irinotecan, 5-fluorouracil, capecitabine, and mercaptopurine.

Comparison of Thrombelastography with Common Coagulation Tests

1981 ◽  
Vol 46 (04) ◽  
pp. 752-756 ◽  
Author(s):  
L Zuckerman ◽  
E Cohen ◽  
J P Vagher ◽  
E Woodward ◽  
J A Caprini
Keyword(s):  
Laboratory Tests ◽  
Clinical Utility ◽  
Blood Clotting ◽  
Strong Relationship ◽  
Relative Strength ◽  
Additional Information ◽  
Patients With Cancer ◽  
Two Samples ◽  
Coagulation Tests ◽  
Common Laboratory

SummaryThrombelastography, although proven as a useful research tool has not been evaluated for its clinical utility against common coagulation laboratory tests. In this study we compare the thrombelastographic measurements with six common tests (the hematocrit, platelet count, fibrinogen, prothrombin time, activated thromboplastin time and fibrin split products). For such comparisons, two samples of subjects were selected, 141 normal volunteers and 121 patients with cancer. The data was subjected to various statistical techniques such as correlation, ANOVA, canonical and discriminant analysis to measure the extent of the correlations between the two sets of variables and their relative strength to detect blood clotting abnormalities. The results indicate that, although there is a strong relationship between the thrombelastographic variables and these common laboratory tests, the thrombelastographic variables contain additional information on the hemostatic process.

scholarly journals A real‐world data of Immune checkpoint inhibitors in solid tumors from India

2021 ◽  
Author(s):  
Vanita Noronha ◽  
George Abraham ◽  
Vijay Patil ◽  
Amit Joshi ◽  
Nandini Menon ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Real World ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Real World Data ◽  
World Data

scholarly journals Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments

2017 ◽  
Vol 5 (5) ◽  
pp. 1280-1287.e2 ◽  
Author(s):  
Richard J. Buka ◽  
Rebecca C. Knibb ◽  
Richard J. Crossman ◽  
Cathryn L. Melchior ◽  
Aarnoud P. Huissoon ◽  
...  
Keyword(s):  
Real World ◽  
Emergency Departments ◽  
Clinical Utility ◽  
Serum Tryptase

scholarly journals Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Shigeo Koido ◽  
Sadamu Homma ◽  
Akitaka Takahara ◽  
Yoshihisa Namiki ◽  
Hideo Komita ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Solid Tumors ◽  
Cancer Vaccines ◽  
Evaluation Criteria ◽  
Cellular Responses ◽  
Antitumor Activities ◽  
Patients With Cancer ◽  
Rational Development ◽  
Immunologic Monitoring ◽  
Early Effects

Although dendritic cell (DC)- based cancer vaccines induce effective antitumor activities in murine models, only limited therapeutic results have been obtained in clinical trials. As cancer vaccines induce antitumor activities by eliciting or modifying immune responses in patients with cancer, the Response Evaluation Criteria in Solid Tumors (RECIST) and WHO criteria, designed to detect early effects of cytotoxic chemotherapy in solid tumors, may not provide a complete assessment of cancer vaccines. The problem may, in part, be resolved by carrying out immunologic cellular monitoring, which is one prerequisite for rational development of cancer vaccines. In this review, we will discuss immunologic monitoring of cellular responses for the evaluation of cancer vaccines including fusions of DC and whole tumor cell.

Abstract 263: Real World Outpatient Treatment Patterns of Patients with Cancer-Associated Venous Thromboembolism in the US

2019 ◽  
Vol 12 (Suppl_1) ◽  
Author(s):  
Jennifer D Guo ◽  
Patrick Hlavacek ◽  
Tayla Poretta ◽  
Gail Wygant ◽  
Daniel C Lane ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Real World ◽  
Outpatient Treatment ◽  
Treatment Patterns ◽  
Patients With Cancer ◽  
The Us

scholarly journals Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

2019 ◽  
Vol Volume 11 ◽  
pp. 4297-4312 ◽  
Author(s):  
Pauline du Rusquec ◽  
Ombline de Calbiac ◽  
Marie Robert ◽  
Mario Campone ◽  
Jean Sebastien Frenel
Keyword(s):  
Solid Tumors ◽  
Clinical Utility ◽  
Evidence Based ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document